Comparative Pharmacology
Head-to-head clinical analysis: BENZAMYCIN versus MAFENIDE ACETATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENZAMYCIN versus MAFENIDE ACETATE.
BENZAMYCIN vs MAFENIDE ACETATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BENZAMYCIN (benzoyl peroxide and clindamycin) combines the keratolytic and antimicrobial actions of benzoyl peroxide with the antibacterial effect of clindamycin, a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit.
Mafenide acetate is a sulfonamide antibiotic that inhibits bacterial folic acid synthesis by competitively antagonizing para-aminobenzoic acid (PABA), thereby preventing bacterial growth. It has broad-spectrum activity against gram-negative and gram-positive organisms, including Pseudomonas aeruginosa.
Topical: Apply a thin layer to affected areas twice daily (morning and evening). Each gram contains 30 mg benzoyl peroxide and 30 mg erythromycin.
Apply topically as a thin layer to affected areas once or twice daily. The dosage form is an 11.1% cream or solution. The cream is applied using a sterile gloved hand; the solution is applied with a sterile spray or brush.
None Documented
None Documented
2.5-3.5 hours in adults with normal renal function; may be prolonged to 4-6 hours in patients with hepatic impairment
Approximately 45 minutes (range 30-60 minutes) for the parent compound; the metabolite p-CBS has a longer half-life of about 4 hours.
Renal excretion: ~70% (30% as unchanged drug, 40% as active metabolite N-desmethylclindamycin); biliary/fecal: ~30%
Renal: approximately 80% excreted unchanged in urine; the remainder is metabolized to p-carboxybenzene sulfonamide (p-CBS) which is also renally excreted.
Category C
Category C
Topical Antibiotic
Topical Antibiotic